These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10856098)

  • 1. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
    Norris B; Pritchard KI; James K; Myles J; Bennett K; Marlin S; Skillings J; Findlay B; Vandenberg T; Goss P; Latreille J; Rudinskas L; Lofters W; Trudeau M; Osoba D; Rodgers A
    J Clin Oncol; 2000 Jun; 18(12):2385-94. PubMed ID: 10856098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
    Reyno L; Seymour L; Tu D; Dent S; Gelmon K; Walley B; Pluzanska A; Gorbunova V; Garin A; Jassem J; Pienkowski T; Dancey J; Pearce L; MacNeil M; Marlin S; Lebwohl D; Voi M; Pritchard K;
    J Clin Oncol; 2004 Jan; 22(2):269-76. PubMed ID: 14722035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy.
    Aziz Z; Rehman A; Qazi S
    Cancer Chemother Pharmacol; 1999; 44 Suppl():S9-S12. PubMed ID: 10602903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
    Vici P; Colucci G; Giotta F; Sergi D; Filippelli G; Perri P; Botti C; Vizza E; Carpino A; Pizzuti L; Latorre A; Giannarelli D; Lopez M; Di Lauro L
    J Exp Clin Cancer Res; 2011 Apr; 30(1):39. PubMed ID: 21481280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
    Nabholtz JM; Falkson C; Campos D; Szanto J; Martin M; Chan S; Pienkowski T; Zaluski J; Pinter T; Krzakowski M; Vorobiof D; Leonard R; Kennedy I; Azli N; Murawsky M; Riva A; Pouillart P;
    J Clin Oncol; 2003 Mar; 21(6):968-75. PubMed ID: 12637459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
    Spielmann M; Dorval T; Turpin F; Antoine E; Jouve M; Maylevin F; Lacombe D; Rouesse J; Pouillart P; Tursz T
    J Clin Oncol; 1994 Sep; 12(9):1764-70. PubMed ID: 8083698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
    Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
    Biganzoli L; Cufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
    J Clin Oncol; 2002 Jul; 20(14):3114-21. PubMed ID: 12118025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
    Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
    Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
    Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
    J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
    Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer.
    Hegg R; Costa MA; Perdicaris M; Delgado GL; Cabral-Filho S; Malzyner A; Caponero R; Yamagushi N; Novaes N; Anelli A; Correa M; Nader L; Andrade C
    Curr Med Res Opin; 2001; 16(4):225-34. PubMed ID: 11268706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study.
    Hochster HS; Vogel CL; Burman SL; White R
    Oncologist; 2001; 6(3):269-77. PubMed ID: 11423674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.